China Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025

Stock News

Mar 20

China Resources Pharmaceutical Group (03320) announced the 2025 financial results for China Resources Boya Bio-Pharmaceutical Group. The company achieved total operating revenue of approximately 2.059 billion yuan, representing a year-on-year increase of 18.69%. However, net profit attributable to shareholders of the listed company was about 113 million yuan, a decrease of 71.61% compared to the previous year. Basic earnings per share were 0.22 yuan. The board proposed a cash dividend distribution of 0.73 yuan per 10 shares (including tax).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168419260"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168419260\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168419260?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168419260","market":"sh","top_or_hot":-1,"title":"China Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025","media":"Stock News","content":"<p>China Resources Pharmaceutical Group (03320) announced the 2025 financial results for China Resources Boya Bio-Pharmaceutical Group. The company achieved total operating revenue of approximately 2.059 billion yuan, representing a year-on-year increase of 18.69%. However, net profit attributable to shareholders of the listed company was about 113 million yuan, a decrease of 71.61% compared to the previous year. Basic earnings per share were 0.22 yuan. The board proposed a cash dividend distribution of 0.73 yuan per 10 shares (including tax).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-20 19:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group (03320) announced the 2025 financial results for China Resources Boya Bio-Pharmaceutical Group. The company achieved total operating revenue of approximately 2.059 billion yuan, representing a year-on-year increase of 18.69%. However, net profit attributable to shareholders of the listed company was about 113 million yuan, a decrease of 71.61% compared to the previous year. Basic earnings per share were 0.22 yuan. The board proposed a cash dividend distribution of 0.73 yuan per 10 shares (including tax).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1168419260","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168419260","pubTimestamp":1774007763,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Pharmaceutical Group (03320) announced the 2025 financial results for China Resources Boya Bio-Pharmaceutical Group. The company achieved total operating revenue of approximately...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300294":"博雅生物","BK0046":"生物疫苗","BK0197":"中小创蓝筹","BK1191":"制药","03320":"华润医药","BK0239":"医药制造","BK1570":"华润系"},"translate_title":"华润医药报告博雅生物制药2025年净利润下降71.61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300294":1,"03320":1},"content_text":"China Resources Pharmaceutical Group (03320) announced the 2025 financial results for China Resources Boya Bio-Pharmaceutical Group. The company achieved total operating revenue of approximately 2.059 billion yuan, representing a year-on-year increase of 18.69%. However, net profit attributable to shareholders of the listed company was about 113 million yuan, a decrease of 71.61% compared to the previous year. Basic earnings per share were 0.22 yuan. The board proposed a cash dividend distribution of 0.73 yuan per 10 shares (including tax).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}